Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewImmunologyInfectious diseaseInflammation Open Access | 10.1172/jci.insight.199201

Excess IL-18 drives fatal mousepox cytokine storm via NK cell immunodeficiency and nonspecific T-cell hyperactivation

Jemy A. Varghese,1 Leonardo Huang,2 Stephen D. Carro,3 Emily E. Landy,4 Anastasia Frank-Kamenetskii,2 Hannah Klinghoffer,2 Jeremy A. Morrissette,2 Vinh Dang,2 Laurence C. Eisenlohr,3 and Scott W. Canna1

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Varghese, J. in: PubMed | Google Scholar |

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Huang, L. in: PubMed | Google Scholar

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Carro, S. in: PubMed | Google Scholar

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Landy, E. in: PubMed | Google Scholar

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Frank-Kamenetskii, A. in: PubMed | Google Scholar

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Klinghoffer, H. in: PubMed | Google Scholar

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Morrissette, J. in: PubMed | Google Scholar

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Dang, V. in: PubMed | Google Scholar

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Eisenlohr, L. in: PubMed | Google Scholar

1Rheumatology and Immune Dysregulation, Children's Hospital of Philadelphia, Philadelphia, United States of America

2Rheumatology and Immune Dysregulation, Children’s Hospital of Philadelphia, Philadelphia, United States of America

3Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, United States of America

4Department of Immunology, University of Pittsburgh, Pittsburgh, United States of America

Find articles by Canna, S. in: PubMed | Google Scholar |

Published October 20, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.199201.
Copyright © 2026, Varghese et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published October 20, 2026 - Version history
View PDF
Abstract

Hemophagocytic Lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with multiple contributors, often including an infectious trigger. The Macrophage Activation Syndrome (MAS) subtype is linked to marked IL-18 excess, cytotoxic T-lymphocyte (CTL) activation, and natural killer (NK) cell abnormalities. We asked how excess IL-18 shapes NK and CTL responses to viral challenge. Mice with chronic IL-18 overproduction (Il18tg), showed baseline NK-cytopenia and CTL activation resembling MAS-susceptible patients. NK transcriptomes reflected IL-18/IFNg-axis activation and cell cycle upregulation. LCMV infection of Il18tg mice causes HLH/MAS without affecting viral control, but is not a significant NK challenge. Early after infection with NK-dependent mousepox, Il18tg NKs failed to activate appropriately, but CTLs quickly hyperactivated and mousepox control remained intact. Mousepox-infected Il18tg mice then developed signs of HLH/MAS including hepatosplenic necrosis. Their viral control was impaired, possibly because they failed to expand mousepox-specific CTLs. Il18bpKO mice, despite more normal resting lymphocytes, succumbed similarly to viremic HLH/MAS. Transfer of pre-activated NKs into Il18tg mice partially rescued virus-specific CTL responses, viral control, and survival. Thus, excess IL-18 contributes to HLH/MAS via disparate effects on CTL and NK cells, demonstrating a novel, context-specific NK immunodeficiency and highlighting how subtle host-pathogen interactions can affect the mechanisms and treatment rationale of life-threatening HLH/MAS.

Supplemental material

View Supplemental Data 1_DEG_GSEA M2_M7

View Supplemental Data 2_Effect of IL-18 in vitro_raw data and GSEA analysis

View Supplemental Data 3_Test of Immature vs Mature_Inputs and GSEA analysis

View Supplemental Methods

View

Version history
  • Version 1 (October 20, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts